Every year, the high-profile academic journal "Science" names ten groundbreaking discoveries in a top list of scientific ...

Local AIDS experts are at odds with the United Nations Programme on HIV/AIDS (UNAIDS) over its claims that AIDS could be ...

In recent years, the investment landscape has seen a significant shift towards socially responsible investing strategies.

2024 — Recent results from a recent clinical trial indicate that a twice-yearly injection of Lenacapavir offers an overall 96% reduced risk of acquiring ... HIV Latency Reversing Properties in ...

Recent research has focused on innovative treatment options, particularly the development of new classes of antiretroviral drugs, such as lenacapavir, which is a first-in-class capsid inhibitor.

In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Buy rating on Gilead Sciences (GILD – Research Report), with a price ...

Dr. Reddy's Laboratories Limited RDY reported third-quarter fiscal 2025 earnings of 20 cents per American Depositary Share ...

We recently compiled a list of the 8 Best Humane Stocks to Invest in Now. In this article, we are going to take a look at ...

Data from both studies showcased the superiority of twice-yearly injectable, lenacapavir, compared to once-daily oral Truvada and background HIV incidence rates, prompting Gilead to unblind the ...

At the 24-week timepoint, 94.2% of the islatravir/lenacapavir regimen still had copies below 50 copies per ml, the limit of detection, which was the same proportion as a group that continued on ...

The first is lenacapavir (Sunlenca) which is the first HIV capsid inhibitor. Lenacapavir is given by injection once every six months, but it needs to be taken in combination with other HIV medicines ...